U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Bright Minds Biosciences DRUG | 0.00 | |
Universal Health Services UHS | 0.00 | |
Alnylam Pharmaceuticals ALNY | 0.00 | |
Vertex Pharmaceuticals VRTX | 0.00 | |
Ionis Pharmaceuticals IONS | 0.00 |
May 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CAVA Group, Eagle Materials and Vertiv Holdings, on Wednesday.
HIGHLIGHTS
* CAVA Group Inc CAVA.N: Jefferies raises target price to $95 from $85 |
* CH Robinson Worldwide Inc CHRW.O: Jefferies raises to buy from hold |
* Eagle Materials Inc EXP.N: JP Morgan raises target price to $225 from $215 |
* Moderna MRNA.O: JP Morgan resumes coverage with underweight rating; price target $40 |
* Vertiv Holdings Co VRT.N: TD Cowen raises target price to $387 from $347 |
Following is a summary of research actions on U.S. companies reported by Reuters on Wednesday. Stock entries are in alphabetical order.
* Alnylam Pharmaceuticals Inc ALNY.O: JP Morgan resumes coverage with overweight rating |
* Alnylam Pharmaceuticals Inc ALNY.O: JP Morgan resumes coverage with PT $420 |
* Biomarin Pharmaceutical Inc BMRN.O: JP Morgan resumes coverage with overweight rating; PT $80 |
* Bright Minds Biosciences Inc DRUG.N: Piper Sandler raises target price to $220 from $190 |
* Brown & Brown Inc BRO.N: JP Morgan cuts target price to $81 from $85 |
* CAVA Group Inc CAVA.N: Jefferies raises target price to $95 from $85 |
* CAVA Group Inc CAVA.N: Piper Sandler raises target price to $92 from $85 |
* CAVA Group Inc CAVA.N: Stifel raises target price to $105 from $90 |
* CH Robinson Worldwide Inc CHRW.O: Jefferies raises to buy from hold |
* CH Robinson Worldwide Inc CHRW.O: Jefferies raises PT to $200 from $195 |
* Eagle Materials Inc EXP.N: JP Morgan raises target price to $225 from $215 |
* Eagle Materials Inc EXP.N: RBC raises target price to $219 from $208 |
* Halozyme Therapeutics Inc HALO.O: JP Morgan resumes coverage with neutral rating; PT $70 |
* Home Depot Inc HD.N: D.A. Davidson cuts target price to $377 from $445 |
* Home Depot Inc HD.N: Jefferies cuts target price to $361 from $454 |
* Home Depot Inc HD.N: JP Morgan cuts target price to $396 from $423 |
* Home Depot Inc HD.N: Piper Sandler cuts target price to $378 from $421 |
* Home Depot Inc HD.N: RBC cuts target price to $340 from $377 |
* Incyte INCY.O: JP Morgan resumes coverage with neutral rating; price target $105 |
* Insmed Inc INSM.O: JP Morgan resumes coverage with overweight rating; price target $180 |
* Ionis Pharmaceuticals Inc IONS.O: JP Morgan resumes coverage with overweight rating; PT $90 |
* Jazz Pharmaceuticals Plc JAZZ.O: JP Morgan resumes coverage with overweight rating; PT $265 |
* Mirum Pharmaceuticals MIRM.O: JP Morgan resumes coverage with overweight rating; PT $115 |
* Moderna MRNA.O: JP Morgan resumes coverage with underweight rating; price target $40 |
* Relay Therapeutics Inc RLAY.O: Leerink Partners raises target price to $29 from $23 |
* Tenet Healthcare Corp THC.N: JP Morgan cuts target price to $260 from $280 |
* United Therapeutics Corp UTHR.O: JP Morgan resumes coverage with overweight rating; PT $685 |
* Universal Health Services Inc UHS.N: JP Morgan cuts target price to $205 from $235 |
* Vertex Pharmaceuticals VRTX.O: JP Morgan resumes coverage with overweight rating; PT $515 |
* Vertiv Holdings Co VRT.N: TD Cowen raises target price to $387 from $347 |